Zespół badawczy Radosława Zagożdżona
Wybrane publikacje
| Publikacja | Impact Factor |
|---|---|
| Zagożdżon AM, O’Leary P, Callanan JJ, Crown J, Gallagher WM, Zagożdżon R. Generation of a new bioluminescent model for visualisation of mammary tumour development in transgenic mice. BMC Cancer 2012; 12: 209. |
3,0 |
| Brennan DJ, O’Connor DP, Laursen H, McGee SF, McCarthy S, Zagożdżon R, Rexhepaj E, Culhane AC, Martin FM, Duffy MJ, Landberg G, Ryden L, Hewitt SM, Kuhar MJ, Bernards R, Millikan RC, Crown JP, Jirstrom K, Gallagher WM. The cocaine- and amphetamine-regulated transcript mediates ligand-independent activation of ERα, and is an independent prognostic factor in node-negative breast cancer. Oncogene 2012; 31: 3483‒3494. |
6,3 |
| Zagożdżon R, Gallagher WM, Crown J. Truncated HER2: implications for HER2-targeted therapeutics. Drug Discov Today 2011; 16: 810‒816. |
6,8 |
| Zagożdżon R, Kamiński R, Fu Y, Fu W, Bougeret C, Avraham HK. Csk homologous kinase (CHK), unlike Csk, enhances MAPK activation via Ras-mediated signaling in a Src-independent manner. Cell Signal 2006; 18: 871‒881. |
4,8 |
| Kamiński R, Zagożdżon R, Fu Y, Mróz P, Fu W, Seng S, Avraham S, Avraham HK. Role of SRC kinases in Neu-induced tumorigenesis: challenging the paradigm using Csk homologous kinase transgenic mice. Cancer Res 2006; 66: 5757‒5762. |
7,6 |
| Lee BC, Lee TH, Zagożdżon R, Avraham S, Usheva A, Avraham HK. Carboxyl-terminal Src kinase homologous kinase negatively regulates the chemokine receptor CXCR4 through YY1 and impairs CXCR4/CXCL12 (SDF-1α)-mediated breast cancer cell migration. Cancer Res 2005; 65: 2840‒2845. |
7,6 |
| Golab J, Zagożdżon R, Kamiński R, Kozar K, Gryska K, Iżycki D, Mackiewicz A, Stokłosa T, Giermasz A, Lasek W, Jakobisiak M. Potentiatied antitumor effectiveness of combined chemo-immunotherapy with interleukin-12 and 5-fluorouracil of L1210 leukemia in vivo. Leukemia 2001; 15: 613‒620. |
4,2 |
| Feleszko W, Zagożdżon R, Jakóbisiak M. Greying of America will foster new strategies in oncology. J Natl Cancer Inst 1998; 90: 247‒248. |
10,7 |
| Golab J, Zagożdżon R, Stokłosa T, Jakóbisiak M, Pojda Z, Machaj E. Erythropoietin prevents the development of interleukin-12-induced anemia and thrombocytopenia but does not decrease its antitumor activity in mice. Blood 1998; 91: 4387‒4388. |
8,3 3,2 |
| Zagożdżon R, Golab J, Stokłosa T, Giermasz A, Nowicka D, Feleszko W, Lasek W, Jakóbisiak M. Effective chemo-immunotherapy of L1210 leukemia in vivo using interleukin-12 combined with doxorubicin but not with cyclophosphamide, paclitaxel or cisplatin. Int J Cancer 1998; 77: 720‒727. | – |